Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: SLS009
DRUG: venetoclax
DRUG: azacitidine

Sponsor

Sellas Life Sciences Group